BioMarin Pharmaceutical Inc. has presented new long-term data on VOXZOGO, or vosoritide, showing sustained effects on arm span, bone mineral measures, and growth-related outcomes in children with achondroplasia. The update, presented at the Pediatric Endocrine Society’s 2026 Annual Meeting, also comes as the rare disease biotechnology firm prepares for pivotal Phase 3 topline data in hypochondroplasia during the first half of 2026.

Why VOXZOGO’s long-term data matters beyond the original growth velocity story

The latest VOXZOGO data matter because they push the clinical discussion beyond the original regulatory anchor of annualized growth velocity and toward a broader question: whether long-term C-type natriuretic peptide pathway modulation can meaningfully influence skeletal proportionality, bone health, and disease burden in children with achondroplasia. That shift is important for clinicians, regulators, and payers because height gain alone, while measurable and commercially important, does not fully capture the multisystem nature of achondroplasia.

Achondroplasia is not simply a condition of short stature. It is a skeletal dysplasia linked to disrupted endochondral bone growth, disproportionate limb development, spinal complications, craniofacial changes, and potential long-term functional challenges. For that reason, any therapy seeking durable clinical relevance must eventually answer a harder question than whether children grow faster over one year. It must show whether the pattern of growth is proportional, whether skeletal health is preserved, and whether earlier intervention can reduce downstream complications.

BioMarin’s new long-term extension data appear designed to strengthen that broader case. Researchers reported improvements in arm span Z-scores across age groups and stability in the arm span-to-height ratio over time, suggesting that treatment did not merely increase linear growth in isolation but supported more proportional skeletal development. That is clinically meaningful because disproportion is one of the defining features of achondroplasia, and improvements in proportionality may carry more relevance for long-term function than height gains alone.

The limitation is that long-term extension studies, while valuable, are not the same as randomized controlled evidence over the full duration of treatment. Comparisons with untreated natural history cohorts can provide important context, especially in rare diseases where extended placebo-controlled follow-up may be impractical or ethically difficult. However, regulators and payers will still examine how robustly these external comparisons control for baseline characteristics, growth variability, age at treatment initiation, and other confounding factors.

How the achondroplasia evidence base is becoming more commercially important for BioMarin

The commercial importance of VOXZOGO has grown because BioMarin is no longer trying to establish whether vosoritide has a biological effect in achondroplasia. That question has largely moved into a different phase. The more pressing issue is whether the therapy can defend and expand its position as the leading pharmacological option in a rare pediatric skeletal disorder where treatment duration, early initiation, caregiver burden, payer scrutiny, and long-term follow-up all matter.

VOXZOGO is already positioned as the only approved treatment for children with achondroplasia starting from birth in certain markets, and BioMarin has described more than a decade of clinical research supporting the therapy. The reported standing height differences in children who initiated treatment after age five, including more than 10 centimeters after six years and more than 13 centimeters after eight years compared with untreated natural history cohorts, provide a long-duration signal that can help physicians and families understand treatment expectations beyond the first few years.

That matters because daily injectable therapy in pediatric rare disease settings requires a durable value proposition. Families, clinicians, and health systems are not only weighing annual growth velocity. They are also considering burden of administration, monitoring, hypotension-related precautions, injection site reactions, duration of therapy, and the uncertainty around whether measurable growth changes translate into broader functional outcomes.

The commercial risk is that the more VOXZOGO expands into early-life use and adjacent indications, the more BioMarin will need evidence that supports outcomes beyond stature. Payers may increasingly ask whether earlier and longer treatment reduces complications, improves mobility, lowers surgical burden, or changes quality-of-life trajectories. Long-term skeletal and proportionality measures are therefore useful, but they are likely to be stepping stones rather than the final evidence package.

Why bone density and arm span data may influence clinician confidence

The new bone mineral content and bone mineral density data are important because any therapy that changes skeletal growth in children must also reassure clinicians that bone health is not being compromised. In the reported study of 119 children who received VOXZOGO, bone mineral content increased over time while bone mineral density Z-scores remained consistent year over year for up to six years. For a therapy used during active growth, that stability is a meaningful safety and durability signal.

The clinical significance lies in the distinction between stimulating growth and maintaining healthy skeletal development. A treatment that increases growth velocity but creates uncertainty around bone strength, mineralization, or proportionality would face a more difficult adoption environment. By showing maintained bone density Z-scores and rising bone mineral content over time, BioMarin is attempting to support the idea that VOXZOGO’s growth effects are not coming at the expense of bone quality.

That said, bone mineral density and bone mineral content are still surrogate or intermediate measures. They help clinicians assess skeletal health, but they do not automatically prove reductions in fractures, orthopedic complications, spinal stenosis, pain, functional limitations, or surgical need. For the field to move further, longer follow-up and real-world registries will be important, especially as treated children age into adolescence and adulthood.

The arm span data may be equally relevant because proportional growth is central to the lived experience of achondroplasia. Stability in the arm span-to-height ratio suggests that VOXZOGO’s effect may be more balanced than a simple height acceleration story. However, clinicians will still want to understand whether proportionality changes translate into functional gains, better reach, improved mobility, or fewer orthopedic interventions. That is where the next wave of evidence will need to go.

What BioMarin’s hypochondroplasia program could change if Phase 3 data are positive

The hypochondroplasia program is the more strategic part of the update because it could determine whether VOXZOGO becomes a broader skeletal dysplasia platform rather than a single-indication rare disease product. BioMarin is expecting topline results from the registration-enabling Phase 3 CANOPY-HCH-3 trial in children with hypochondroplasia in the first half of 2026, with potential regulatory submissions in the second half of the year if results are positive.

Hypochondroplasia shares biological relevance with achondroplasia through FGFR3-related skeletal growth disruption, but it is generally considered a distinct clinical condition with different severity, recognition patterns, and diagnostic pathways. That distinction matters commercially and clinically. A positive Phase 3 result would not simply expand the label. It could validate BioMarin’s broader thesis that vosoritide can be applied across related skeletal growth disorders where C-type natriuretic peptide pathway activity may offset excessive FGFR3 signaling.

The Phase 2 data from children with hypochondroplasia, including statistically significant improvements in total body minus head bone mineral density and bone mineral content after 12 months, provide supportive context. However, the pivotal readout will need to answer the core regulatory and clinical questions more directly. Regulators will focus on efficacy, safety, population definition, endpoint relevance, and whether benefits are sufficiently meaningful for a condition that may present with variable severity.

The unresolved issue is market definition. Achondroplasia is well recognized as the most common skeletal dysplasia associated with disproportionate short stature, while hypochondroplasia can be underdiagnosed or diagnosed later. If approved, BioMarin may need to invest in disease education, genetic confirmation pathways, specialist referral networks, and payer frameworks that distinguish appropriate use from broader short stature treatment. That creates opportunity, but also opens the door to more scrutiny over patient selection.

Why earlier treatment could become the next major debate in skeletal dysplasia care

BioMarin’s messaging around early intervention is strategically important because VOXZOGO’s commercial model depends partly on treatment duration. If clinicians become more confident that early treatment produces greater cumulative benefit, the addressable treatment window expands and the value proposition strengthens. The company’s position that long-term and early treatment are critical reflects the biological logic of acting while growth plates remain open.

From a clinical perspective, earlier treatment makes sense if the goal is to influence growth during the most active phases of skeletal development. In pediatric endocrinology and rare skeletal disorders, timing often determines the magnitude of response. The longer a child remains untreated during active growth, the less remaining developmental runway may be available. That makes early diagnosis, referral, and initiation central to VOXZOGO’s real-world impact.

However, early treatment also raises higher evidentiary expectations. Starting therapy in infancy or early childhood means families and clinicians are committing to years of daily injections in a population that cannot personally consent in the same way older children can. That places greater weight on long-term safety, tolerability, caregiver feasibility, and confidence that benefits will be meaningful beyond growth charts.

This is where real-world evidence will become increasingly important. Clinical trials can establish efficacy and controlled safety signals, but adoption in very young children depends on daily-use realities. Injection training, adherence, hypotension precautions, routine monitoring, and access support all become part of the therapeutic profile. BioMarin’s ability to support families and clinicians operationally may therefore influence uptake almost as much as the clinical data.

What risks remain as VOXZOGO moves into a broader evidence phase

The main risk for BioMarin is not that VOXZOGO lacks a clinical effect. The larger risk is that the definition of success continues to evolve faster than the evidence base. Annualized growth velocity helped secure regulatory approval and early adoption, but the market is now asking more mature questions about proportionality, complications, durability, quality of life, and health-economic value.

The accelerated approval context in the United States also matters. VOXZOGO’s U.S. indication is based on improvement in annualized growth velocity, with continued approval potentially contingent on verification and description of clinical benefit in confirmatory studies. BioMarin intends to use ongoing open-label extension studies compared with available natural history data to fulfill that post-marketing requirement. That approach is practical in a rare disease setting, but it also places pressure on the quality and interpretability of long-term comparative evidence.

Safety will remain part of the debate as use broadens. The most commonly discussed risks include injection site reactions, vomiting, joint pain, stomachache, decreased blood pressure, and elevated blood alkaline phosphatase levels. For most clinicians, these risks must be weighed against the potential benefits of long-term growth modification and skeletal development. For payers, the risk-benefit calculation will also be linked to cost, duration, and measurable outcomes.

Competitive risk is another factor, even if VOXZOGO currently holds a strong position. Rare disease markets often attract follow-on mechanisms once a first therapy validates the biology and commercial pathway. BioMarin’s advantage lies in long-term data, regulatory experience, and real-world treatment exposure. To maintain that advantage, the U.S.-based biotech firm will need to keep expanding the evidence base in ways that competitors cannot easily replicate.

What clinicians, regulators, and industry observers will watch next

The next major inflection point is the CANOPY-HCH-3 topline readout in hypochondroplasia. A positive result could give BioMarin a credible path toward a second skeletal dysplasia indication and strengthen VOXZOGO’s identity as a platform therapy. A mixed or modest result would not necessarily undermine the achondroplasia franchise, but it would narrow expectations for indication expansion and could make investors more cautious about the broader growth story.

Clinicians will watch whether future datasets connect skeletal measurements with functional outcomes. Arm span, height, bone mineral density, and bone mineral content are important, but the field will increasingly ask whether treated children experience better mobility, reduced pain, fewer procedures, improved daily function, or lower complication burden. That is the evidence layer that could move VOXZOGO from a growth-modifying therapy to a broader disease-modifying intervention in clinical perception.

Regulators will focus on whether the long-term data are sufficiently rigorous to support continued confidence in benefit, especially where natural history comparisons are used. Payers will focus on whether early and long-duration use can be justified by measurable clinical value. Families and clinicians will focus on whether daily therapy is manageable and whether the benefits remain meaningful over time.

BioMarin’s latest VOXZOGO update therefore lands at an important point in the product’s lifecycle. The therapy has moved beyond the launch-era question of whether it can increase growth velocity. The more important question now is whether long-term treatment can reshape the broader clinical trajectory of children with achondroplasia and potentially related skeletal dysplasias. That is a higher bar, but also a larger opportunity.

  achondroplasia, BioMarin Pharmaceutical Inc., CANOPY-HCH-3, hypochondroplasia, Pediatric Endocrine Society, pediatric endocrinology, rare disease biotechnology, skeletal dysplasia, vosoritide, VOXZOGO